Jared Kaltwasser

Inflammatory microenvironments appear to enhance melanoma cells’ ability to control T-cell responses.

Patients with reduced DNA mismatch repair protein expression were more likely to respond to immune checkpoint inhibitors (ICIs), although this study had a small sample size.

A new review article shows positive trends in survival, as scientists better understand the different types and symptoms of pulmonary arterial hypertension (PAH).

Patient education is an important step toward improving outcomes for racial and ethnic groups disproportionately affected by lupus, but a new report suggests payers and physicians also have more to learn about the problem.

A new review article highlights a number of roles for B1 cells, including antibody secretion and the stimulation of CD4+ cells.

Investigators said these differences might help explain why some patients have better outcomes than others with combination immune checkpoint blockades.

Expression of the chemokine receptor was linked with better overall survival.

The research could pave the way for therapies that target enhancers of disease-related genes.

It is not yet clear what impact proactive screening might have on health care costs and survival outcomes.

Black children with systemic lupus erythematosus (SLE) are at the highest risk of adverse renal outcomes, the study found.

Panic disorders and specific phobias were the mental disorders most often seen among individuals who have chronic thromboembolic pulmonary hypertension (CTEPH), according to new research.

In this case, a patient died 18 months following his transplant after developing de novo intrahepatic cholangiocarcinoma.

Of 5 RNA investigated, 2 correlated with systemic lupus erythematosus and the last correlated with certain inflammation-related symptoms.

Levosimendan appeared to increase in-hospital survival rates, although no long-term survival benefit was reported, among patients with comorbid heart failure and connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH).

Investigators say it may soon be possible to design therapies better at staving off resistance among patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), which is an incurable disease.

Relapse remains a daunting reality in multiple myeloma, but clinicians have more tools to work with to fight the disease.

A new review article shows diabetes and hypertension are linked with arrhythmia and chronic kidney disease (CKD), but several other less common causes also exist.

The 5-year survival rate over the time period was just 33.8%, the study found.

The report is based on a series of 10 cases and a literature review involving 14 cases.

The authors of a new study say patients with certain mutations appear to respond to zanubrutinib, which had a favorable safety profile.

A new report shows better than 80% concordance between liquid biopsy and tissue biopsy.

Chronic kidney disease (CKD) and diabetes were associated with a higher risk of neurocognitive decline, but kidney disease stage did not appear to affect risk.

Investigators also studied omega-6, but they found no evidence that it is involved in causing systemic lupus erythematosus (SLE).

Advances in whole genome sequencing are helpful in linking genetic variants with diseases, but the process is more challenging in cases of rare and ultra-rare diseases.

Existing research appears to suggest these patients can be treated similarly to patients with other genetic subtypes of cutaneous melanomas.

Approaches such as new types of monoclonal antibodies and chimeric antigen receptor natural killer cells could change how chronic lymphocytic leukemia is treated, according to a recent review article.

The mortality rate for patients with systemic lupus erythematosus (SLE) was greater than one-third if they were admitted to an intensive care unit (ICU).

The meta-analysis found insufficient evidence to assess the validity of the screening in diagnosing age-related macular degeneration.

About 15% of cases of large granular lymphocytic leukemia involve natural killer cells.

A new review article outlines the latest research and results into programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).